Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
AVITA Medical, Inc. (RCEL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/02/2023 |
8-K
| Quarterly results |
08/16/2023 |
4
| O'Toole David D (CFO) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Bought 1,000 shares
@ $17.05, valued at
$17.1k
Bought 1,000 shares
@ $17.06, valued at
$17.1k
|
|
08/15/2023 |
4
| O'Toole David D (CFO) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Bought 1,000 shares
@ $17.92, valued at
$17.9k
Bought 1,000 shares
@ $17.89, valued at
$17.9k
Bought 1,000 shares
@ $17.96, valued at
$18k
Bought 1,000 shares
@ $17.94, valued at
$17.9k
Bought 1,000 shares
@ $17.93, valued at
$17.9k
|
|
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
8-K
| Quarterly results
Docs:
|
"AVITA Medical Reports Second Quarter Financial Results VALENCIA, California, August 10, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023. Financial Highlights and Recent Updates • Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022 • Received Food and Drug Administration approval of premarket approval supplement for the use of RECELL to treat full-thickness skin defects on June 7 • Initiated commercial launch of full-thickness skin defects, along with additional eligible burn procedures, with expanded U.S. comm..." |
|
06/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/16/2023 |
4
| O'Toole David D (CFO) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 150,000 options to buy
@ $17, valued at
$2.6M
|
|
06/16/2023 |
3
| O'Toole David D (CFO) has filed a Form 3 on AVITA Medical, Inc. |
06/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer VALENCIA, Calif., June 15, 2023 and MELBOURNE, Australia, June 16, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public companies. O'Toole will play a critical role in ex..." |
|
06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/08/2023 |
4
| Vance Cary Guy (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 10,374 shares
@ $0 Granted 6,175 shares
@ $0 Granted 4,446 options to buy
@ $14.17, valued at
$63k
Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/08/2023 |
4
| Shiroma Donna (General Counsel) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 60,000 options to buy
@ $14.17, valued at
$850.2k
|
|
06/08/2023 |
4
| REED JAN STERN (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 6,175 shares
@ $0 Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/08/2023 |
4
| Quick Andrew (Chief Technology Officer) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 60,000 options to buy
@ $14.17, valued at
$850.2k
|
|
06/08/2023 |
4
| Panaccio Lou (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 6,175 shares
@ $0 Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/08/2023 |
4
| McNamara Robert (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 10,374 shares
@ $0 Granted 6,175 shares
@ $0 Granted 4,446 options to buy
@ $14.17, valued at
$63k
Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/08/2023 |
4
| Ekins Sean (Interim CFO) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 30,000 options to buy
@ $14.17, valued at
$425.1k
|
|
06/08/2023 |
4
| Crowe Suzanne (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 6,175 shares
@ $0 Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/08/2023 |
4
| CORBETT JAMES (CEO) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 100,000 options to buy
@ $14.17, valued at
$1.4M
|
|
06/08/2023 |
4
| COOK JEREMY CURNOCK (Director) has filed a Form 4 on AVITA Medical, Inc.
Txns:
| Granted 6,175 shares
@ $0 Granted 2,646 options to buy
@ $14.17, valued at
$37.5k
|
|
06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/26/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
04/25/2023 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
04/21/2023 |
8-K
| Quarterly results |
04/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/04/2023 |
3
| McNamara Robert (Director) has filed a Form 3 on AVITA Medical, Inc. |
04/04/2023 |
3
| Vance Cary Guy (Director) has filed a Form 3 on AVITA Medical, Inc. |
04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
03/27/2023 |
8-K
| Quarterly results |
03/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/21/2023 |
8-K
| Quarterly results |
03/08/2023 |
8-K
| Other Events Interactive Data |
|
|
|